Healthcare
YD Bio Limited Ordinary Shares(YDES)
Live Price
Offline$2.42
-3.97% today
Window Change
-42.17%
Window
Aug 28, 2025 → Jun 1, 2026
- Market Cap
- $350.00M
- Revenue Growth
- +45.8%
- EPS Growth
- -280100.0%
- Dividend Yield
- 0.0%
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 190 bars · Aug 28, 2025 → Jun 1, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
YD Bio Limited Ordinary Shares (YDES) is a Healthcare stock with a market cap of $350.00M and listed on NASDAQ. The stock last traded around $2.42 and down 42.2% across the available one-year price window (Aug 28, 2025 → Jun 1, 2026). Baseline metrics include revenue growth of +45.8%, EPS growth of -280100.0%, a dividend yield of 0.0%. What stands out right now is revenue +45.8%, EPS -280100.0%, free cash flow -8386.3% with operating margin 0.0% and ROIC 13.6%. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines YDES price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+45.8% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at +45.8% and EPS is at -280100.0%, with operating margin around 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
YDES
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
YDES Max Drawdown
-86.74%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for YDES and SPY.
Company Overview
YD Bio Limited Ordinary Shares
NASDAQ Global Select
Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.
- Leadership
- Ethan Shen
- IPO Date
- Aug 29, 2025
- Employees
- 4
- Street Address
- No. 3, Xingnan St.
- Mailing
- Taipei, 115001
- Region
- Taipei, TW
- Reporting Currency
- USD
- Investor Line
- +82 2 546 1611
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- —
Growth
- Revenue
- +45.8%
- EPS
- -280100.0%
- Free Cash Flow
- -8386.3%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 68.2%
- ROIC
- 13.6%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.02
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.